These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 23567651

  • 1. Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease.
    Febbraro F, Sahin G, Farran A, Soares S, Jensen PH, Kirik D, Romero-Ramos M.
    Neurobiol Dis; 2013 Aug; 56():47-58. PubMed ID: 23567651
    [Abstract] [Full Text] [Related]

  • 2. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease.
    McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ.
    J Neuropathol Exp Neurol; 2009 May; 68(5):515-24. PubMed ID: 19525899
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.
    Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, Muzyczka N.
    Proc Natl Acad Sci U S A; 2008 Jan 15; 105(2):763-8. PubMed ID: 18178617
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M, Kirik D, Björklund A.
    Brain; 2011 Aug 15; 134(Pt 8):2302-11. PubMed ID: 21712347
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A.
    J Neurosci; 2002 Apr 01; 22(7):2780-91. PubMed ID: 11923443
    [Abstract] [Full Text] [Related]

  • 13. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG, Bensadoun JC, Aebischer P, Schneider BL.
    J Parkinsons Dis; 2011 Apr 01; 1(4):373-87. PubMed ID: 23939344
    [Abstract] [Full Text] [Related]

  • 14. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P.
    Proc Natl Acad Sci U S A; 2002 Aug 06; 99(16):10813-8. PubMed ID: 12122208
    [Abstract] [Full Text] [Related]

  • 15. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
    Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M.
    Eur J Neurosci; 2010 Aug 06; 32(3):409-22. PubMed ID: 20704592
    [Abstract] [Full Text] [Related]

  • 16. Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra.
    Khodr CE, Pedapati J, Han Y, Bohn MC.
    Dev Neurobiol; 2012 Jun 06; 72(6):906-17. PubMed ID: 22021082
    [Abstract] [Full Text] [Related]

  • 17. Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration.
    Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papasilekas T, Papadopoulou-Daifoti Z, Kirik D, Stefanis L.
    Brain; 2013 Jul 06; 136(Pt 7):2130-46. PubMed ID: 23757764
    [Abstract] [Full Text] [Related]

  • 18. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors.
    Van der Perren A, Toelen J, Casteels C, Macchi F, Van Rompuy AS, Sarre S, Casadei N, Nuber S, Himmelreich U, Osorio Garcia MI, Michotte Y, D'Hooge R, Bormans G, Van Laere K, Gijsbers R, Van den Haute C, Debyser Z, Baekelandt V.
    Neurobiol Aging; 2015 Mar 06; 36(3):1543-58. PubMed ID: 25599874
    [Abstract] [Full Text] [Related]

  • 19. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
    Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E.
    Neuroscience; 2012 Feb 17; 203():170-9. PubMed ID: 22198020
    [Abstract] [Full Text] [Related]

  • 20. Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?
    Cinar E, Yalcin-Cakmakli G, Saka E, Ulusoy A, Yuruker S, Elibol B, Tel BC.
    Exp Neurol; 2020 Aug 17; 330():113357. PubMed ID: 32437708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.